Evaluation of the Cost and Effectiveness in the First-line Treatment of Advanced Renal Cell Cancer With Sunitinib Compared to Interferon-alfa in Finland.
- Clinically indicated first-line sunitinib treatment for advanced RCC.
- Informed consent obtained.
- Unable to complete HRQoL forms.
- Not consenting to collecting register data.
Type of Study:
Observational Model: Cohort, Time Perspective: Prospective
Incremental cost per incremental time to treatment failure (TTF) in first-line treatment
Outcome Time Frame:
Finland: Finnish Medicines Agency
- Renal Cell Carcinoma
- renal cell cancer
- quality of life
- Carcinoma, Renal Cell